CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Begin main content

Home Resources Evidence Bundles Evidence on the Use of IVIG

Evidence Bundles

Evidence on the Use of IVIG

You’ll find our best evidence on using intravenous immunoglobulin (IVIG) – on label or off label – to treat different medical conditions.

We’ve selected the following materials to get you started:

Off-Label Use of Intravenous Immunoglobulin (IVIG) (In Brief: A Summary of the Evidence, November 2018)
Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection: A Review of Clinical Effectiveness (Summary With Critical Appraisal, April 2018)
Off-Label Use of Intravenous Immunoglobulin for Dermatological Conditions: A Review of Clinical Effectiveness (Summary With Critical Appraisal, April 2018)
Off-Label Use of Intravenous Immunoglobulin for Autoimmune or Inflammatory Conditions: A Review of Clinical Effectiveness (Summary With Critical Appraisal, April 2018)
Off-Label Use of Intravenous Immunoglobulin for Hematological Conditions: A Review of Clinical Effectiveness (Summary With Critical Appraisal, March 2018)
Off-Label Use of Intravenous Immunoglobulin for Neurological Conditions: A Review of Clinical Effectiveness (Summary With Critical Appraisal, March 2018)

Health Technology Assessments

Summaries of Abstracts

Summaries With Critical Appraisal

Tools and Resources